Phase 2 Efficacy and Safety of Frexalimab: 6-Month Results of a Novel CD40L Inhibitor in Relapsing Multiple SclerosisPatrick Vermersch,Cristina Granziera,Yang Mao-Draayer,Gary Cutter,Oleksandr Kalbus,Ivan Staikov,Michal Dufek,Stephane Saubadu,Raphael Bejuit,Philippe Truffinet,Biljana Djukic,Erik Wallstroem,Gavin GiovannoniMULTIPLE SCLEROSIS JOURNAL（2023）引用 0|浏览27暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
